BOSTON / Oct 04, 2023 / Business Wire / Amwell® (NYSE: AMWL), a global leader in hybrid care enablement, is attending the HLTH 2023 conference, Oct. 8-10, in Las Vegas. During the conference, Amwell executives will meet with interested parties to discuss the future of digital health, the evolution of virtual primary care and newly announced strategic partnerships that strengthen the organization’s ability to advance hybrid care, benefiting patients, providers, and the healthcare system.
Amwell leaders will participate in the following panels and events during the conference:
Sunday, Oct. 8
Monday, Oct. 9
Additionally, Amwell clients will be speaking in the following keynote sessions:
Monday, Oct. 9
Tuesday, Oct. 10
For more information about the organization’s HLTH activities or to request a meeting with an Amwell leader during the event, contact This email address is being protected from spambots. You need JavaScript enabled to view it., and follow @amwell on X and LinkedIn.
About Amwell
Amwell provides a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. The company offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the hybrid care of more than 55 health plans, which collectively represent more than 90 million covered lives, and many of the nation’s largest health systems, representing over 2,000 hospitals, have access to Amwell solutions. For more information, please visit https://business.amwell.com/.
©2023 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Last Trade: | US$6.98 |
Daily Change: | -0.04 -0.57 |
Daily Volume: | 53,414 |
Market Cap: | US$95.420M |
February 12, 2025 January 15, 2025 December 18, 2024 October 30, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load